Sugi Predict

Sugi Predict / Compounds / SCHEMBL896275

SCHEMBL896275

SCHEMBL896275

O=C(Nc1cncc(Br)c1)Oc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.58
▸ ALDH1A1 P00352 6/20 0.51
▸ MAPT P10636 4/20 0.51
▸ RAD51 Q06609 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ KDM4E B2RXH2 2/20 0.49
▸ MEN1 O00255 3/20 0.48
▸ THRB P10828 1/20 0.48
▸ GFER P55789 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ GAA P10253 3/20 0.48
▸ HTT P42858 2/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ LMNA P02545 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ HDAC4 P56524 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ ALOX15 P16050 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9383638 0.84 ALDH1A1 (0.54) KMT2AALDH1A1MAPTRAD51CYP1A2
SCHEMBL12515433 0.82 ALDH1A1 (0.51) KMT2AALDH1A1MAPTRAD51CYP1A2
SCHEMBL31065612 0.82 CYP1A2 (0.57) KMT2AALDH1A1MAPTRAD51CYP1A2
SCHEMBL897080 0.82 POLB (0.52) KMT2AALDH1A1MAPTRAD51CYP1A2
SCHEMBL32671986 0.82 CNR1 (0.57) KMT2AALDH1A1MAPTRAD51CYP1A2
SCHEMBL896497 0.82 ALDH1A1 (0.55) KMT2AALDH1A1MAPTRAD51CYP1A2
SCHEMBL896790 0.82 ALDH1A1 (0.51) KMT2AALDH1A1MAPTRAD51CYP1A2
SCHEMBL12991338 0.82 ALDH1A1 (0.51) KMT2AALDH1A1MAPTRAD51CYP1A2
SCHEMBL21227888 0.81 ALDH1A1 (0.61) KMT2AALDH1A1MAPTRAD51CYP1A2
SCHEMBL11132897 0.80 KMT2A (0.82) KMT2AALDH1A1MAPTRAD51CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3305073-B1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED LLC (US) 2019-05-15 — — EP disclosed
US-10105370-B2 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2018-10-23 — — US disclosed
US-20180256588-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) 2018-09-13 — — US disclosed
EP-3305073-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF Samumed, LLC (US) 2018-04-11 — — EP disclosed
US-9855272-B2 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2018-01-02 — — US disclosed
EP-3001903-B1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED LLC (US) 2017-10-25 — — EP disclosed
EP-3001903-B1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF SAMUMED LLC (US) 2017-10-25 — — EP disclosed
US-20170202846-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2017-07-20 — — US disclosed
US-20170202846-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2017-07-20 — — US disclosed
US-9446035-B2 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2016-09-20 — — US disclosed
US-8450340-B2 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof SAMUMED, LLC (US) 2013-05-28 — — US disclosed
EP-2515655-A1 1H-PYRAZOLO[3,4-BETA]PYRIDINES AND THERAPEUTIC USES THEREOF Samumed, LLC (US) 2012-10-31 — — EP disclosed
US-20120083476-A1 HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA NV (BE) 2012-04-05 — — US disclosed
US-20120083476-A1 HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA NV (BE) 2012-04-05 — — US disclosed
US-20120083476-A1 HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA NV (BE) 2012-04-05 — — US disclosed
US-20110190290-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF EPITHERIX, LLC (US) 2011-08-04 — — US disclosed
US-20110190290-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF EPITHERIX, LLC (US) 2011-08-04 — — US disclosed
WO-2011084486-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF EPITHERIX, LLC (US) 2011-07-14 — — WO disclosed
WO-2010141817-A1 HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA NV (BE) 2010-12-09 — — WO disclosed
WO-2010141817-A1 HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA NV (BE) 2010-12-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190290-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF BRCA1, THPO, PDXK KMT2A 2698/4885ALDH1A1 123/4885MAPT 2756/4885
US-20170202846-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF BRCA1, THPO, PDXK KMT2A 2698/4885ALDH1A1 123/4885MAPT 2756/4885
US-10105370-B2 1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof BRCA1, THPO, PDXK KMT2A 2698/4885ALDH1A1 123/4885MAPT 2756/4885
US-20120083476-A1 HETEROARYL-SUBSTITUTED SPIROCYCLIC DIAMINE UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, DBH KMT2A 656/4885ALDH1A1 709/4885MAPT 1489/4885
US-20180256588-A1 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF BRCA1, THPO, PDXK KMT2A 2698/4885ALDH1A1 123/4885MAPT 2756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.